Weekly Funding Opportunities

[Med Research]

Funding for COVID-19 Projects (New Non-COVID-19-related Opportunities Follow the COVID-19 List)

While FSU’s Office of Research Development is the best source for COVID-19 federal funding opportunities<https://www.research.fsu.edu/research-offices/ord/funding-opportunities-related-to-covid-19/#fundingOps>, below are a few that are off-the-beaten path. Terra Bradley<mailto:terra.bradley at med.fsu.edu> is happy to help you pick through those at ORD or below and identify the best sources of funding for your COVID-19 projects.

British Society for Antimicrobial Chemotherapy: COVID-19 Research Grants<https://urldefense.com/v3/__http://bsac.org.uk/bsac-covid-19-funding-call/__;!!PhOWcWs!kU1fhsspMLWgbtD5duRKWiUwWNHM2dVnYCPAjIHWMy3_vz_4suMW50KY9ETcLzyM6vGSdJO-NyZXOfFITqY$ >
Grants of up to £25,000 to support research projects. Exceptional grants in excess of £25,000 will be considered. The funding scope covers projects of up to 12 months only:

  *   New projects
  *   Extension of existing research projects
  *   Expenditure of staff and or consumables
Applications are open worldwide to all organisations and will be subject to a rapid peer review process.
Research findings will be considered for fast track open access online publication in JAC or  JAC-AMR.
Expressions of interest, in the form of a single-page A-4 summary should be submitted to grants at bsac.org.uk<mailto:grants at bsac.org.uk> by Friday, 17 April. Given the tight deadline, please alert Med-RA<mailto:research at med.fsu.edu> as soon as possible if you intend to submit a single-page A-4 summary to this competition.

Johns Hopkins Bloomberg School of Public Health: Fast-Track Grant For Research on Non-Animal Approaches to Investigate Mechanisms, Medicines, and Vaccines for Coronaviruses<https://urldefense.com/v3/__https://caat.jhsph.edu/programs/grants/2020-2021*20Grant*20Application*20Kit*20COVID-19.pdf__;JSUlJQ!!PhOWcWs!kU1fhsspMLWgbtD5duRKWiUwWNHM2dVnYCPAjIHWMy3_vz_4suMW50KY9ETcLzyM6vGSdJO-NyZXN060e6o$ >
In response to the global COVID-19 pandemic, the Johns Hopkins Center for Alternatives to Animal Testing (CAAT) at the Bloomberg School of Public Health is redirecting part of our grant program to help accelerate the discovery of mechanisms, medicines, and vaccines for COVID-19. The program's goal is to centralize information and stimulate funding of the development of non-animal, human biology-based models to help coordinate and accelerate response to current and emerging pandemics. Funding: $40,000.
Due April 30, 2020. Given the tight deadline, please alert Med-RA<mailto:research at med.fsu.edu> as soon as possible if you intend to submit to this competition.

Harrington Scholar Award for Coronavirus<https://urldefense.com/v3/__https://www.uhhospitals.org/harrington-discovery-institute/funding-and-programs/harrington-scholar-award-coronavirus__;!!PhOWcWs!kU1fhsspMLWgbtD5duRKWiUwWNHM2dVnYCPAjIHWMy3_vz_4suMW50KY9ETcLzyM6vGSdJO-NyZXztra0Y4$ >
Harrington Discovery Institute (HDI) will provide successful applicants with grant funding and expert guidance and oversight in all aspects of drug/therapeutics development, while taking no rights to intellectual property, which is retained by the award recipient and their institution. HDI will select up to ten projects through the call for proposals and its current portfolio of drugs in development. Awarded projects will run for 12 months, with the possibility of extending the engagement.
Award recipients will receive:

  *   $150k guaranteed, with the potential to receive up to $1 million in charitable support.
  *   Dedicated drug discovery and development support from Harrington Discovery Institute’s Therapeutics Development team (experienced pharma and business development team with a track record of bringing new drugs to market).
  *   A personalized team of drug developers and project manager for every award recipient.
  *   Select access to partners that range from non-profit, foundation, and public sector organizations to private drug development and investment companies.
Projects being sought:

  *   Novel therapies that can target Coronavirus and its co-morbidities, such as impact on lungs and heart.
  *   Broad-spectrum anti-viral therapies, particularly targeting respiratory viruses.
  *   Next generation vaccines that may target new Corona strains, multiple Corona viruses or more than one type of virus.
  *   Emergency countermeasures/prophylaxis strategies for first responders and emergency medical personnel to be administered either once or short term.
Emphasis of call:

  *   Therapies that can enter clinical trials near-term (i.e., within 12 months) with HDI project management and financial support.
  *   Breakthrough, differentiated technologies and discoveries.
Due April 30, 2020. Given the tight deadline, please alert Med-RA<mailto:research at med.fsu.edu> as soon as possible if you intend to submit to this competition.

Would you like to meet with a federal agency regarding a product that you are developing for COVID-19? Request a CoronaWatch meeting.<https://urldefense.com/v3/__https://www.medicalcountermeasures.gov/Request-BARDA-TechWatch-Meeting/__;!!PhOWcWs!kU1fhsspMLWgbtD5duRKWiUwWNHM2dVnYCPAjIHWMy3_vz_4suMW50KY9ETcLzyM6vGSdJO-NyZX4a_kZO8$ >
The U.S. government, in response to the COVID-19 outbreak, seeks information from stakeholders on available medical countermeasures in development. We are particularly interested in products and technologies that have progressed into or beyond non-clinical trials, have established large-scale cGMP manufacturing capability, or utilize an approved platform. Information regarding diagnostics, therapeutics, vaccines, and other products or technologies relevant to addressing this outbreak are sought. At this time, we ask for a brief description of your product or technology, accompanied by a slide deck, manuscript, publications, or other non-confidential information of your choosing. Please note that while we will use any information you present as market research, submission is no guarantee of a meeting or funding and your submission will be shared across U.S. Government agencies involved in COVID-19 medical countermeasure research and development.  Only U.S. government officials are invited to join a CoronaWatch meeting, and are bound by law to maintain confidentiality of what is presented and discussed. Ideal technologies and products would (but are not required to) be:

  *   Relevant to the U.S. government COVID-19 medical countermeasure research and development efforts and/or Emerging Infectious Disease rapid response capabilities
  *   Utilize an already-approved platform, have non-clinical data suggesting efficacy, and/or have significant manufacturing capability
  *   Fully owned or licensed by your organization (you have full IP rights and/or freedom to operate)
Meeting requests reviewed on an ongoing basis. Please alert Med-RA<mailto:research at med.fsu.edu> as soon as possible if you intend to request a CoronaWatch meeting.

SARS-CoV-2 diagnostics: performance data<https://urldefense.com/v3/__https://www.finddx.org/covid-19/dx-data/__;!!PhOWcWs!kU1fhsspMLWgbtD5duRKWiUwWNHM2dVnYCPAjIHWMy3_vz_4suMW50KY9ETcLzyM6vGSdJO-NyZXMdTQNyI$ >: A Potential Data Source and Repository for Your Data
FIND is conducting independent evaluations of SARS-CoV-2 molecular tests<https://urldefense.com/v3/__https://www.finddx.org/covid-19/sarscov2-eval-molecular/__;!!PhOWcWs!kU1fhsspMLWgbtD5duRKWiUwWNHM2dVnYCPAjIHWMy3_vz_4suMW50KY9ETcLzyM6vGSdJO-NyZXtVkYtt8$ > and immunoassays<https://urldefense.com/v3/__https://www.finddx.org/covid-19/sarscov2-eval-immuno/__;!!PhOWcWs!kU1fhsspMLWgbtD5duRKWiUwWNHM2dVnYCPAjIHWMy3_vz_4suMW50KY9ETcLzyM6vGSdJO-NyZXSBtGsmA$ >. Data from these evaluations will be shared on the FIND page as soon as possible. To complement these evaluations, and in partnership with WHO in line with our official Collaborating Centre remit, we are endeavouring to centralize the collection of SARS-CoV-2 diagnostic performance data as a global public good. On 27 March 2020, we published an open call<https://urldefense.com/v3/__https://www.finddx.org/wp-content/uploads/2020/03/COVID-19_Dx-performance-data-sharing_FINAL-27.03.2020.pdf__;!!PhOWcWs!kU1fhsspMLWgbtD5duRKWiUwWNHM2dVnYCPAjIHWMy3_vz_4suMW50KY9ETcLzyM6vGSdJO-NyZXctyWqL8$ > to partners and laboratories around the world for any performance data on commercially available in vitro diagnostic tests for SARS-CoV-2 that detect nucleic acid, viral antigen or antibodies. These data will be made openly accessible on our website and shared with WHO, in order to help inform procurement and implementation decisions for countries and health programmes – specifically those with limited capacity to conduct their own independent evaluations. All data are welcome, with as much (or little) detail as possible. The data dashboard is growing daily. Use the data and / or submit your own any time. Please alert Med-RA<mailto:research at med.fsu.edu> as soon as possible if you intend to submit your data to FIND.

Pfizer COVID-19 Competitive Grant Program<https://urldefense.com/v3/__https://pfe-pfizercom-prod.s3.amazonaws.com/GMG_2020GMG_G-COVID-19.pdf__;!!PhOWcWs!kU1fhsspMLWgbtD5duRKWiUwWNHM2dVnYCPAjIHWMy3_vz_4suMW50KY9ETcLzyM6vGSdJO-NyZXOn3BRmQ$ >
During this challenging time, Pfizer is committed to doing all they can to respond to the COVID-19 pandemic. We recognize the need for the rapid development of educational programs and trainings and the implementation of systemic best practices for COVID19 management. As part our commitment, we are releasing this Request for Proposals (RFP) to provide financial support for organizations producing independent educational programs and quality improvement initiatives designed to combat this evolving crisis. Through this RFP, we intend to support educational programs for healthcare providers focused on the recognition, diagnosis, treatment, and overall care management of patients with COVID-19. Specific topics of interest include:

  *   Overview of the epidemiology, virology, and clinical features of COVID19;
  *   Summary of the criteria for testing and interpreting results of laboratory testing;
  *   Recommendations for managing patients with COVID-19 at home and in the hospital;
  *   Counsel for preventing transmission in the clinic and in the community;
  *   Review of investigational treatments;
  *   Guidance for managing special patient populations during the COVID19 pandemic;
  *   Retraining on COVID-19 relevant medical procedures (e.g. ventilator management) for clinicians returning to the work force;
  *   Guidelines on the correct use and procedures of personal protective equipment (PPE).
In addition, we are interested in supporting programs that include tools designed to help HCP’s educate patients and caregivers on the disease state, preventative measures, and emerging strategies for COVID-19 treatment.
Due May 22, 2020. Med-RA deadline to receive draft documents: May 11, 2020.

Research Grant for Pandemic Preparedness<https://urldefense.com/v3/__https://www.emdgroup.com/en/research/open-innovation/2020-research-grants/research-grant-pandemic-preparedness.html__;!!PhOWcWs!kU1fhsspMLWgbtD5duRKWiUwWNHM2dVnYCPAjIHWMy3_vz_4suMW50KY9ETcLzyM6vGSdJO-NyZXmg16SvE$ >
The threat from newly emerging viral infections is one of the top global challenges for humanity. The recent COVID-19 pandemic shows that pandemic preparedness and having the right products and technology to fight infectious diseases with epidemic and pandemic potential is of utmost importance. It is required to act quickly to limit further substantial damages to society, economy and ecology. Project proposals will be considered that leverage modern technologies to create new breakthrough solutions to be more prepared for pandemic outbreaks or work towards existing solutions that could help to fight emerging viral infections. Proposals will be considered that leverage technological solutions to be more prepared for pandemic outbreaks or solutions that could help to fight emerging viral infections. This is a global competition. 250,000 €/year for 3 years with the option of extension.
Pre-outbreak R&D Preparedness for pandemic disease:

  *   Assessing the priority of pathogens and diseases with epidemic threat;
  *   Platform technologies to accelerate the development of vaccines, drugs, diagnostics, vector control tools and delivery systems needed to control emerging health threats;
  *   Innovative technologies for better personal protection equipment for infection control.
Response during outbreak:

  *   Novel health technologies (e.g. AI, bioelectronics, diagnostics) for early screening of potential infected patients and treatment facilitation;
  *   Fast-track identifying, testing and production of effective drugs and vaccines during outbreak.
Due August 31, 2020. Med-RA deadline to receive draft documents: August 18, 2020.

Other Recently Released Non-COVID-19 Opportunities

Gerber Foundation<https://urldefense.com/v3/__https://www.gerberfoundation.org/how-to-apply/__;!!PhOWcWs!kU1fhsspMLWgbtD5duRKWiUwWNHM2dVnYCPAjIHWMy3_vz_4suMW50KY9ETcLzyM6vGSdJO-NyZXeJNyzNg$ >
The Gerber Foundation is dedicated to enhancing the quality of life of infants and young children, with an emphasis on children under three years of age. The foundation is accepting applications for research projects aimed at identifying solutions to common everyday issues and problems in the field of children’s health and nutrition. Of particular interest to the foundation are projects offering substantial promise of meaningful advances in prevention and treatment of disease and those with broad and general applicability. Research program focus areas identified by the foundation include:
Pediatric Health: Projects that promote health and prevent or treat disease. Of particular interest to the foundation are applied research projects focused on reducing the incidence of neonatal and early childhood illnesses, or those improving cognitive, social, and emotional aspects of development.
Pediatric Nutrition: Projects that assure adequate nutrition to infants and young children, including applied research that evaluates the provision of specific nutrients and their related outcomes.
Environmental Hazards (Nutrient Competitors): Projects that document the impact of, or ameliorate the effects of, environmental hazards on the growth and development of infants and young children.
Major target areas for research include new diagnostic tools that may be more rapid, more specific, more sensitive, or less invasive; treatment regimens that are novel, less stressful or painful, more targeted, have fewer side effects, and/or provide optimal dosing; symptom relief; preventative measures; assessment of deficiencies or excesses (vitamins, minerals, drugs, etc.); and risk assessment tools or measures for environmental hazards, trauma, etc. The foundation is interested in supporting projects that will result in “new” information, treatments, or tools that result in a change in practice; it rarely funds projects that are focused on sharing current information with parents or caregivers.
Eligible applicants must be tax exempt under section 501(c)(3) of the Internal Revenue code. (Public governmental institutions such as universities are included in this definition.) With few exceptions, organizations must have their principal operations in the United States.
Novice researchers follow the same process as regular grants, are limited to no more than $20,000 in total funding, and need to apply under the guidance of a mentor.
Concept paper due May 15, 2020 and November 15, 2020. Med-RA deadline to receive draft documents for the May 15, 2020 deadline: May 4.

Research on Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) (R 21 / R01 Clinical Trials Not Allowed)
R21<https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/pa-files/PAR-20-168.html__;!!PhOWcWs!kU1fhsspMLWgbtD5duRKWiUwWNHM2dVnYCPAjIHWMy3_vz_4suMW50KY9ETcLzyM6vGSdJO-NyZX0f_aM4U$ >
R01<https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/pa-files/PAR-20-165.html__;!!PhOWcWs!kU1fhsspMLWgbtD5duRKWiUwWNHM2dVnYCPAjIHWMy3_vz_4suMW50KY9ETcLzyM6vGSdJO-NyZXGp7vdoM$ >
This Funding Opportunity Announcement (FOA) encourages investigator(s)-initiated applications that propose to examine the etiology, diagnosis, pathophysiology and manifestations of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) in diverse groups and across the lifespan. Applications that address gaps in the understanding of the environmental and biological risk factors, the determinants of heterogeneity among individuals with ME/CFS, and the common mechanisms influencing the multiple affected body systems in ME/CFS are encouraged. The NIH is particularly interested in funding interdisciplinary research that will enhance our knowledge of disease processes and provide evidence-based solutions to improve the diagnosis, treatment, and quality of life of all persons with ME/CFS. This interdisciplinary research may include the building of scientific teams to study and develop biomarkers and/or characterize the pathophysiological response of organ systems in individuals with ME/CFS. Applicants are encouraged to propose novel and innovative research that will break new ground or extend previous discoveries toward new directions.
Standard dates apply. Expires May 8, 2023. Med-RA deadline to receive draft documents for June 5, 2020 R01 standard date: May 26. Med-RA deadline to receive draft documents for June 16, 2020 R21 standard date: June 3.

Reducing Stigma Related to Drug Use in Human Service Settings (R21 / R34 Clinical Trial Optional)
R21<https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-21-002.html__;!!PhOWcWs!kU1fhsspMLWgbtD5duRKWiUwWNHM2dVnYCPAjIHWMy3_vz_4suMW50KY9ETcLzyM6vGSdJO-NyZX_v4t5Bc$ >
R34<https://urldefense.com/v3/__https://grants.nih.gov/grants/guide/rfa-files/rfa-da-21-001.html__;!!PhOWcWs!kU1fhsspMLWgbtD5duRKWiUwWNHM2dVnYCPAjIHWMy3_vz_4suMW50KY9ETcLzyM6vGSdJO-NyZXJ_MVhHA$ >
One of the most important barriers to the provision and utilization of HIV prevention and care services is stigma, which is defined as an identity marked by disgrace, disapproval or shame, which often leads to discriminatory treatment by others. This funding opportunity supports formative research to support the development of stigma reduction interventions, as well as pilot or feasibility studies of new or adapted interventions to reduce stigma that impedes the provision and utilization of HIV care and prevention services.
Due August 11, 2020. Med-RA deadline to receive draft documents: July 29, 2020.

To search for additional funding opportunities, please visit CoM’s unofficial funding opportunities blog<https://urldefense.proofpoint.com/v2/url?u=https-3A__fsucomgrants.wordpress.com_&d=DwMGaQ&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=-WQkPIXZLCgXlX-d14DY8B-SG-GvP9FZHr_Gv8sUuTQ&s=ErAzzubGxiJsWCKGnlFjfXV6980C-DCl-AxzFLHMVYQ&e=>.



-------------- next part --------------
An HTML attachment was scrubbed...
URL: <http://lists.fsu.edu/pipermail/com_funding_opportunities/attachments/20200415/c363687c/attachment.html>